V Chotteau has ≥ 25 years of experience in mammalian cell culture including ≤ 10 years in biopharmaceutical industry. Her expertise covers process development (perfusion, fed-batch, stem cell bioprocessing, small-, pilot- and commercial scale, GMP). V Chotteau has worked at Pharmacia Upjohn/Biovitrum, Stockholm, (nowadays Swedish Orphan Biovitrum) between 1996 and 2008 with different responsibilities: project manager for process development (e.g. recombinant factor VIII ReFacto®, antibody), CDMO business development support for the evaluation of new projects, head of pilot plant, expert in animal cell culture development (small, pilot and commercial size/GMP). In 2008, consequently to the retirement of Prof. Lena Häggström, formerly leading the animal cell cultivation activities, V Chotteau was offered to lead these activities, due to her expertise in cell culture and her industrial background. Since then, her group has focused on cell-based processes for biopharmaceutical production and on bioprocessing of human stem cell. In May 2013, V Chotteau became Coordinator of EU-FP7 project HESUB, nr. 601700, a project aiming at developing a new perfusion bioreactor for human stem cell culture in controlled environment. Her group has also performed/is performing several projects of perfusion process at high cell density, metabolic flux analysis and development of fed-batch process for biopharmaceutical production (two of these processes have been transferred to CMO for GMP production, of which one is in clinical phase III). V Chotteau is currently supervising/co-supervising 3 researchers, 1 post-doc, 4 PhD students, 1 lab engineer and 1 technician.